Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
-
Shares outstanding
-
41,123,390
-
Total 13F shares
-
15,481,857
-
Share change
-
-864,797
-
Total reported value
-
$45,523,508
-
Price per share
-
$2.94
-
Number of holders
-
21
-
Value change
-
-$4,266,786
-
Number of buys
-
8
-
Number of sells
-
13
Institutional Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q1 2022
As of 31 Mar 2022,
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,481,857 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, Artal Group S.A., Redmile Group, LLC, ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., AXA S.A., BlackRock Inc., Woodline Partners LP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
21
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.